Numinus (NUMI) received Health Canada approval to research the plants that are used to make ayahuasca and a mescaline-containing cactus called San Pedro.
Toronto, Ontario–(Newsfile Corp. – February 28, 2022) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) (“Red Light Holland” or the “Company“), an Ontario-based corporation is pleased to announce its wholly owned subsidiary SR Wholesale in the Netherlands (“SR Wholesale“), has signed an exclusive distribution deal with Conor McGregor’s innovative sports recovery line, TIDL Sport.
Figure 1: SR Wholesale signs exclusive distribution deal with TIDL Sport – Conor McGregor’s innovative Sports Recovery line.
TIDL Sport products combine plant based therapy with exercise science and cryotherapy to assist active lifestyle enthusiasts. True sports recovery goes beyond temporary pain relief, and TIDL Sport products are scientifically curated with ingredients that target inflammation, the foundation of post exercise pain and soreness. The products have been clinically proven to reduce pain and aim to help consumers return to the activities that they love sooner, and pain free.
“I’ve been putting extra focus on my overall health for years now, which is why I’m so pleased that TIDL Sport is partnering with Red Light Holland. Our combined efforts to distribute products with the goal of education around sports recovery – both mentally and physically are where Red Light Holland and TIDL Sport are progressive and aligned.” said Conor McGregor.
TIDL Sport products are designed for the active lifestyle, no matter what the sport. Consumers range from weekend warriors to professional athletes, all whom recognize the importance of recovery and self care. The products focus on different segments of recovery, including relief with the current products and a pipeline that focuses on body recharge and nutrient replenishment.
“We are delighted to be partnering with Conor McGregor and The Anthos Group as Red Light Holland’s wholly-owned subsidiary SR Wholesale plans to be a big part of the distribution for Conor’s next generation sports recovery line – TIDL Sport,” said Todd Shapiro, CEO and Director of Red Light Holland. “The foundation of TIDL Sport and Conor McGregor are completely aligned with Red Light Holland. Together we believe in naturally occurring therapies, healthy and active lifestyles and living in the moment with the goal of long-term recovery while focusing on the betterment of physical and mental health. We see a large opportunity to educate around recovery and wellness and look forward to working closely with Conor and Badal Shah, Chief Executive Officer at The Anthos Group now and into the future.”
“One of Red Light Holland’s focus for 2022 is Mind to Toe wellness. Everyone at SR Wholesale is very excited to now have the access to distribute TIDL Sport, especially in the Netherlands and potentially across Europe – where Conor McGregor is beloved!” said Hans Derix, President of Red Light Holland.
Under the terms of the deal, Red Light Holland’s wholly-owned subsidiary SR Wholesale’s territory to distribute TIDL Sport, shall mean the country of The Netherlands and on a case by case basis, where no there is no conflict with an existing TIDL Sport Distributor, into all regions of Europe.
The brand’s flagship product, the TIDL Sport Plant-Powered Cryotherapy Topical Spray, delivers powerful relief through cryotherapy and novel plant science, delivering immediate pain relief and leaving athletes feeling refreshed as a part of the active lifestyle. The revolutionary topical spray has 360° spray technology for easy, full body self-application and promotes long term healing by addressing pain and inflammation directly at the source. The plant based ingredients in TIDL Sport range from plant derived extracts to well known anti-inflammatory agents that are all organic in nature. The enhanced touch-free formula sprays on clean with an immediate cooling relief, which increases blood flow to the site of application and enables the plant based ingredients to self absorb and go to work.
In addition, the Company’s board of directors approved the grant of 6,600,000 options and awarded 850,000 restricted stock units to certain directors, officers, and consultants of the Company. Each option will entitle the holder thereof to acquire one common share in the capital of Company for a period of three years from the date of issuance, which is expected to on or before March 7, 2022, at an exercise price equal to the greater of (i) $0.12, and (ii) the Company’s closing price on the Canadian Securities Exchange on the day prior to issuance, and subject to the terms and conditions of the Company’s stock option plan. The options will vest quarterly at the end of each fiscal quarter of the Company’s 2023 fiscal year. The options granted to directors of the Company are compensation for their services over the fiscal year ending March 31, 2023. All options and restricted stock units awards will be subject to a hold period of four months plus one day from the date of issuance.
About Red Light Holland
Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles.
For additional information on the Company:
Todd Shapiro
Chief Executive Officer & Director
Tel: 647-643-TRIP (8747)
Email: Todd@RedLight.co
Website: www.RedLight.co
About TIDL Sport
TIDL Sport infuses plant powered therapy with fitness and nutrition science to meet the needs of athletes to perform at the highest level. The flagship product is a plant-powered cryotherapy topical spray that has 360° spray technology for easy, full body self-application. TIDL Sport products are available in select national retailers in the U.S., globally in over 25 countries, and on the company website: www.tidlsport.com
Forward-Looking Statements
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, certain of which are beyond the control of Red Light Holland. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Forward looking statements include, but are not limited to: statements with respect to the Company’s plans for its wholly-owned subsidiary SR Wholesale to be a big part of the distribution for Conor’s next generation sports recovery line – TIDL Sport, the Company’s plans to work with Conor and Badal Shah in the future, and statements with respect to the Company’s business focus in 2022.
Forward-looking information is based on a number of key expectations and assumptions made by Red Light Holland, including without limitation: the COVID-19 pandemic impact on the Canadian economy and Red Light Holland’s business, the Company’s ability to carry out its plans with respect to SR Wholesale distributing Conor’s products, the willingness and ability of Conor and Badal Shah to continue working with SR Wholesale and the Company, no change to laws or regulations that negatively affect Red Light Holland’s business; there will be a demand for Red Light Holland’s products in the future; no unanticipated expenses or costs arise. Although the forward-looking information contained in this news release is based upon what the Company believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the inability of the Company to continue as a going concern; the inability of the Company to obtain all necessary governmental and/or other regulatory approvals, licenses, and permits necessary to operate and expand the Company’s facilities; the effect of regulatory and/or political change and its effect on the legislation and regulations surrounding the psychedelics industry; negative perception of the medical-use and adult-use psilocybin industry; the potential unviability of psilocybin for medical and/or scientific purposes; the inability of the Company to continue its growth; the Company’s limited operating history; reliance on management; the Company’s requirements for additional financing; and competition for mental health and wellness investments.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
Vancouver, B.C. – February 15, 2021: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FRA: YG3) (“Better Plant” or the “Company”) is pleased to announce the execution of a binding letter agreement (the “Letter Agreement”) dated February 14, 2022, with respect to a reverse merger transaction (the “Transaction”) between Better Plant, Metaversive Networks Inc. (“Metaversive”) and 1233392 B.C. Ltd., a wholly owned subsidiary of the Company (“Subco”). The resulting issuer from the Transaction (the “Resulting Issuer”) will carry on the current business of Metaversive.
The Transaction is expected to be treated as a fundamental change in accordance with the policies of the Canadian Securities Exchange (the “CSE”). As a result, trading in the common shares of the Company is currently halted in accordance with the policies of the CSE and will remain halted until such time as all required documentation in connection with the Transaction has been filed with and accepted by the CSE and permission to resume trading has been obtained from the CSE.
About Metaversive
Metaversive is a private corporation in the business of developing a simulated digital environment in the Augmented Metaverse called FreedomX that will use augmented reality, virtual reality, artificial intelligence, 3D and blockchain, along with concepts from social media, to create spaces for rich user interaction and commerce in a digitally simulated v-marketplace world that is integrated with the real world. The platform is anticipated to be beta launched at www.freedomX.com in May 2022.
Freedomx will be launched as a virtual mall social media metaverse where influencers, creators, brands and everyone can bridge the gap between physical and augmented metaversive experiences with virtual goods, games, avatars while interacting, buying, playing, selling, and ranking products and services. FreedomX is a social impact ESG-based platform that is built with accessibility technology and uses blockchain and AI to certify and create trusted user profiles while keeping data ownership.
The Transaction
Under the terms of the Letter Agreement, the Transaction will be completed by way of a three-cornered amalgamation between Better Plant, Metaversive and Subco, pursuant to which Metaversive and Subco will amalgamate to form one corporation (“Amalco”) and Better Plant will acquire 100% of the issued and outstanding common shares of Metaversive (each, a “Metaversive Share”) from the holders of the Metaversive Shares in exchange for common shares of Better Plant (each, a “BPS Share”) on a 1:1 basis. Upon the closing of the Transaction, Amalco will become a wholly-owned subsidiary of the Resulting Issuer. In connection with the Transaction, Better Plant will reconstitute its board of directors and senior officers and promptly following the closing of the Transaction, Better Plant will change its corporate name and the Resulting Issuer will conduct its business under the new name.
At the conclusion of the Transaction, the largest shareholder of the Resulting Issuer will be Ztudium Inc., a company owned by Dinis Guarda. Ztudium is a leading global maker of industry 4IR Fourth Industrial Revolution technologies and research. Ztudium builds software, research products and service solutions, using blockchain, AI and digital transformation DNA. It creates proprietary leading platforms, software products for businesses and governments. Ztudium is part of the EU AI Alliance and has built a global ecosystem reaching over 10 million people a month and has built a revolutionary set of SaaS and media products.
Although Better Plant and Metaversive have certain directors, officers and shareholders in common, the transaction is not anticipated to be subject to the conditions of Multilateral Instrument 61-101 Protection of Minority Security Holders is Special Transactions. Consideration for the acquisition of Metaversive will be one post-consolidation share of Better Plant issued for every outstanding share of Metaversive at the time of closing. More details on the consideration and financial information of Metaversive will be provided at a later date.
The completion of the Transaction is subject to the satisfaction of various conditions that are customary for a transaction of this nature, including but not limited to (i) the negotiation of an amalgamation agreement that will supersede the Letter Agreement and set out in full the terms of the Transaction (the “Amalgamation Agreement”); (ii) the delivery of audited financial statements of Metaversive; (iii) the completion of a consolidation of the BPS Shares at the ratio of one (1) new share for every two (2) existing shares; (iv) the approval of the Transaction by a special majority of the shareholders of Metaversive; and (v) the receipt of all requisite regulatory, stock exchange or governmental authorizations and consents, including the authorization and consent of the CSE.
At this time, the Company and Metaversive are in the process of completing their respective due diligence investigations of the other party and anticipate entering into the Amalgamation Agreement on or before March 23, 2022, with the closing date of the Transaction scheduled to occur no later than May 6, 2022. There can be no assurance that the Transaction will be completed on the terms described in the Letter Agreement or at all.
Pursuant to the Letter Agreement, each of Better Plant and Metaversive is permitted to complete a pre-closing equity financing consisting of units for gross proceeds of up to $3,000,000. Each unit will consist of one share and one half-warrant, with each whole warrant exercisable into one share at a price and for a term to be determined by the parties. All units that may be issued by Metaversive in advance of the closing of the Transaction will be exchanged into a corresponding number of units of the Resulting Issuer on a one-to-one basis.
Management of the Resulting Issuer
Subject to applicable shareholder and regulatory approval, upon completion of the Transaction, the board of directors and management of the Resulting Issuer will be comprised, in part, of the following individuals:
Dinis Guarda, Director and Chief Executive Officer – Mr. Guarda is regularly featured as “top 1, 5, 10, 20 most influential global personalities by Thinkers360.com and many others’ in technology, blockchain, fintech, AI, smart cities, and social media lists. Mr. Guarda is a keynote speaker in events with governments and runs a Youtube podcast that ranks top 1869 in the World in SocialBlade Tech Rank where he interviewed personalities like the Minister of Science and Technology of Japan. Mr Guarda is a serial entrepreneur and some of his achievements include: creating a bank between Asia, and Africa, Advising strategies and building technologies for governments in Europe, Africa and Asia, and working with the likes of UN, Mastercard, Philips, Barclays, IBM and Hyperloop Transportations among other global organizations and corporations. He is the founder of Ztudium Limited, Citiesabc.com, Intelligenthq.com, fashionabc.com, and OpenBusinessCouncil.org. He has been a guest lecturer in leading business schools like Copenhagen and is the author of “4IR – AI Blockchain Fintech IoT – Reinventing a Nation”, “How Businesses & Governments Can Prosper with Blockchain AI Tech”, and “Metaverse NTFs Uprising – The citiesabc Ultimate Guide To Non-Fungible-Tokens and the web 3.0 new Agora the Metaverse(s)”’. Mr. Guarda’s personal social media and group website outreach have monthly direct access to over 10 million users. He also contributes to and has been featured in CNBC, Forbes, Yahoo and Fortune.
Spiros Margaris, Director – Mr. Margaris is a venture capitalist, futurist, keynote speaker, board member and senior advisor. He is the founder of Margaris Ventures, and is the first international influencer to achieve ‘The Triple Crown’ ranking (the No. 1 Fintech, Artificial Intelligence (AI) and Blockchain influencer by Onalytica). He was also ranked the global No. 1 Finance Influencer by Refintiv (Thomson Reuters). Mr. Margaris was named The Key Opinion Leader (KOL) in Fintech (Who’s Who in Fintech?) by Onalytica. He regularly appears in the top three positions of established global industry influencer rankings. Two fintech startups he advised have become unicorns (valuations of over $1 billion: wefox and STC Pay). He is a keynote speaker at international FinTech and InsurTech conferences. He also gave a TEDxAcademy Talk and published an AI white paper, “Machine learning in financial services: Changing the rules of the game,” for the enterprise software vendor SAP.
Penny White, Director – Mrs. White’s experience as an entrepreneur includes online music, international film distribution, mobile payments, blockchain technology, crowdsourcing, renewable energy, pharmaceuticals, eCommerce, law and consumer products. She has been recognized on PROFIT Magazine’s W100 list of top Canadian female entrepreneurs. Under her leadership as CEO, her law firm, Bacchus Law Corporation, was in the PROFIT 500 Fastest Growing companies in 2015 and 2016 based on revenues. Penny has extensive experience in capital markets and has been involved in over 100 private to public transactions. She was a co-founder and an initial director and officer of Merus Labs Inc., which had revenues of $111 million in fiscal 2016 and was acquired by Norgine B.V. in July 2017 for approximately $342 million. Penny is recognized as a thought leader and regularly participates as an expert speaker for keynotes and panels on Capital-raising and Fintech, including CryptoHQ, alongside the World Economic Forum in Davos in 2018. Penny has been featured in The National Post, The Globe and Mail, BNN, Chatelaine, Business in Vancouver, Breakfast Television and more. Penny is also a published author for Forbes as a former member of the invite-only, Forbes Technology Council. She has a Certificate in Leading Sustainable organizations and a Certificate in Fighting Climate Change, both from Oxford University.
Hilton Supra, Director – Mr. Supra is the CBDO and co-founder of Ztudium Limited projects techabc and openbusinessescouncil.org citiesabc.com and its leading technology iDNA, an ecosystem specialized in bridging the best of AI, Fintech, and Blockchain. With more than 30 years of Banking and Asset Management experience in London from Quantitative Asset Management, Capital Markets, Hedge Funds, and Private Equity. Hilton has worked in London for Morgan Grenfell, Deutsche Bank, AXA Rosenberg Investment Management, EIM Fund of Hedge Funds, and Cheyne Capital. Hilton has always been on the leading edge of innovation in banking, capital markets, derivative trading, quantitative asset management, hedge funds, and since 2015 the application of blockchain, AI, and fintech 360 especially in the financial and investment industries.
Additional Information
The completion of the Transaction is subject to a number of conditions, including but not limited to, the acceptance of the CSE and if applicable, shareholder approval. Where applicable, the Transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the Transaction will be completed as proposed or at all.
No directors or 10% owners of Better Plant have any interest in Metaversive but the Transaction may be characterized as a related party transaction as the President and CEO of Better Plant, Penny White, is a director, shareholder and President of Metaversive.
Investors are cautioned that, except as disclosed in the management information circular or listing statement to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon.
The securities referenced herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any applicable state securities laws and may not be offered or sold in the United States or to, or for the account or benefit of, a person in the United States or a U.S. person (as defined in Regulation S under the U.S. Securities Act) absent registration under the U.S. Securities Act and any applicable state securities laws, or compliance with an exemption therefrom. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.
For additional Information on Better Plant Sciences Inc:
Penny White
President, Chief Executive Officer & Director
1-833-515-2677
About Better Plant
Better Plant is in the business of selling consumer products.
The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such risks, uncertainties and factors include, but are not limited to: risks related to the completion of the Transaction; risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19; the potential for not acquiring any rights as a result of the Company’s patent application; risks that any products making use of the intellectual property may be ineffective or the Company may be unsuccessful in commercializing them; that other approvals will be required before commercial exploitation of the intellectual property can happen; demand for the Company’s products; general business, economic, competitive, political and social uncertainties; delay or failure to receive board or regulatory approvals where applicable; and the state of the capital markets. Better Plant cautions readers not to place undue reliance on forward-looking statements provided by the Company, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better Plant expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
Highlights:
Creso Pharma Limited (ASX:CPH, OTC:COPHF, FRA:1X8) (‘Creso Pharma’ or ‘the Company’) is pleased to provide the following update on proposed acquisition target, Sierra Sage Herbs LLC (refer ASX announcement: 3 February 2022) and planned growth initiatives over the coming months.
Based in Denver, Colorado SSH is leading consumer packed goods company with a focus on plantbased and CBD products. SSH provides pioneering products under their Green Goo, Southern Butter and goodgoo brands. The Green Goo and Southern Butter ranges are currently sold across 90,000 distribution points in the US including CVS, Walgreens Walmart, AmazonUS and Target.com, with a further 20,000 points of distribution expected during Q1 CY2022. The acquisition of SSH will mark Creso Pharma’s maiden entry into the US providing the Company access to world’s largest and fastest growing CBD market, which is expected to reach US$12Bn by 2026ii.
Creso Pharma and SSH management continue to work collaboratively to complete the acquisition, which is expected to close in late March or early April 2022. Further, both parties have advanced a number of product development initiatives. Since announcement of the proposed transaction, the Creso Pharma and SSH senior management teams have held numerous extensive meetings to outline plans for accelerating market penetration of both companies’ respective product ranges.
SSH anticipates the launch of a new line of herbal ‘immunity’ deodorants which boast ingredients including functional mushrooms and other herbal formulations in February 2022. The functional mushrooms sector was of initial interest, developing products that exploit certain mushroom varieties which can deliver unique health benefits. The line is being launched under the Green Goo brand and will initially be sold through retailers including CVS, Army & Air Force Exchange Service (AAFES), AmazonUS and Natural Grocers Vitamin Cottage amongst others.
Additional products have been earmarked for development in the Q1 CY2022 include the introduction of a Valentine’s Day massage oil and pillow spray launched by Southern Butter. Green Goo is also expecting the expansion of its distribution network for several different product ranges for pain relief, skincare, and oral care.
Creso Pharma is confident that product development initiatives coupled with SSH’s established retail partner network will result in an immediate increase in sales. The acquisition establishes a footprint for the Company in the USA and provides a strong foundation to accelerate the growth of its sports CBD brand ImpACTIVE.
CEO and Managing Director, Mr William Lay said: “In a short amount of time, the strong synergistic benefits resulting from the proposed acquisition are being witnessed with the launch of the new Green Goo immunity deodorant. Both management teams have been working collaboratively to progress the acquisition as well as actively strategizing ways to increase market penetration of both the Creso Pharma and Green Goo product ranges into new markets.
“SSH has a well-established vast network of key retailers which we plan to leverage for these new products as well as introducing Creso Pharma’s product suite of innovative CBD products. We expect to see an immediate increase in our sales as we benefit from SSH’s existing revenue streams, and synergies between the two companies. I look forward to updating shareholders on the continuing work with SSH as we move to finalising the acquisition at the upcoming shareholder meeting.”
-Ends
Authority and Contact Details
This announcement has been authorised for release by the Board of Directors of Creso Pharma Limited.
For further information, please contact:
Investor Enquiries
Creso Pharma Limited
E: info@cresopharma.com
P: +61 (0) 497 571 532
About Creso Pharma
Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals.
It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and lifestyle products with wide patient and consumer reach for human and animal health.
Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: www.cresopharma.com
Creso Pharma offices:
Australia
Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009
Switzerland
Allmendstrasse 11, 6310 Steinhausen, Schweiz
Canada
59 Payzant Drive, Windsor, Nova Scotia, B0N 2TO and 50 Ivey Ln, Windsor, Nova Scotia, B0N 2TO
Forward Looking statements
This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance, and condition. These statements generally can be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ
materially from expectations include, among other things, general economic and market factors, competition and government regulation.
The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.
i https://www.globenewswire.com/news-release/2021/11/15/2334409/0/en/Global-functional-mushroom-market-to-reach-19-33-billion-by-2030-Allied-Market-Research.html
ii https://content.brightfieldgroup.com/2021-us-cbd-market-report
Calgary, AB – February 10, 2022 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”) a life sciences company with a mission to transform the world of addiction treatment through medicalized ibogaine and a state of the art ongoing care program, is pleased to advise it has entered a Memorandum of Understand (the “MOU”) with Osoyoos Indian Band Development Corporation (“OIBDC”).
Osoyoos Indian Band
Osoyoos Indian Band is a world leader in indigenous business. OIBDC has generated hundreds of millions of dollars of revenue on its lands through tourism, leasing and construction related endeavors, joint ventures and partnerships with globally recognized brands such as Hyatt and Jackson-Triggs. The Osoyoos Indian Band has 540 members and its territory spans over 32000 acres of the warmest lands in Canada located in the Okanagan valley of British Columbia, between Osoyoos and Oliver.
MOU Objectives
The MOU has as its objective, participation of both organizations for purpose and profit, to construct an ibogaine centered detox clinic and holistic aftercare treatment centre. The partners will act as collaborators in bridging economic and social models that respect Indigenous ways while leveraging Western scientific practices. Partnership opportunities may include leasing or joint venture with possibilities to convert existing space or new construction. The development timeline will coincide with the planned Health Canada approval process of the Universal Ibogaine treatment protocol.
Chief Ian Campbell – Chairman Universal Ibogaine
Chief Ian Campbell of the Squamish Nation and UI Board Chair shared “The primary focus for Universal Ibogaine is to bring this life saving medicine to those who need it as quickly as possible. This potential partnership between UI and the Osoyoos Indian Band demonstrates what is possible when we work together towards a solution.”
Chief Clarence Louie – Osoyoos Indian Band
Clarence Louie is a globally recognized indigenous leader and has served as the elected Chief of the Osoyoos Indian Band for close to 40 years. He is a sought-after speaker and holder of innumerable awards, including an Order of Canada and membership in the Canadian Business Hall of Fame. Chief Clarence stated, “We are pleased with the opportunity to partner on this venture and bring opportunities for economic inclusion and deep healing for many people to our lands.”
Nick Karos – CEO Universal Ibogaine
Nick Karos, recently appointed CEO of Universal Ibogaine added “We are excited for this developing relationship. The Osoyoos Indian Band is one of the most proactive and forward-looking groups we have had the opportunity to engage with. We have a big job ahead, and partners like Osoyoos Indian Band add huge credibility to our mission and can aid in diversifying our business opportunities and the planned ultimate deployment of the ibogaine addiction treatment protocol”.
Mike Campol – COO Osoyoos Indian Band Development Corporation
“The opioid epidemic is a public health emergency. We have to do better than opioid substitution therapy. What we have here is an opportunity to be part of a transformation in the way that society treats those who suffer, views plant medicine, and understands indigenous culture. We are pleased to see where this collaboration can take us.”
About Universal Ibogaine Inc.
UI is a life sciences company, with a mission to demonstrate the safety and efficacy of its ibogaine based drug detox protocol through a Canadian Clinical Trial, and ultimately to utilize that protocol around the globe through future licensing agreements. UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Clinic that, which when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS
THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS
RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such as “plans”, “expect”, “project”, “intend”, “will”, “believe”, “anticipate”, “estimate”, “scheduled”, ”potential”, or other similar words, or statements that certain events or conditions “may”, “should” or ”could” occur. The forward-looking statements and information are based on certain key expectations and assumptions made by UI. Although UI believes that the expectations
and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because UI can give no assurance that they will prove to be correct.
Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks, which include, but are not limited to, risks that required regulatory approvals are not obtained. The reader is cautioned that assumptions used in the preparation of such information, although considered reasonable by UI at the time of preparation, may prove to be incorrect
and readers are cautioned not to place undue reliance on forward-looking information, which speaks only to conditions as of the date hereof. UI does not undertake any obligation to release publicly any revisions to forward-looking information contained herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.
For further information:
Investor Relations: Dugan Selkirk, IR Manager
dugan.selkirk@universalibogaine.com
Media Contact: Cathy Fernandes, Director – Marketing & Communications
cathy.fernandes@universalibogaine.com
Broadens audience of investors, allowing YourWay to expand shareholder base and improve awareness, access, and liquidity
VANCOUVER, BC, Feb. 10, 2022 /PRNewswire/ – YourWay Cannabis Brands Inc. (CSE: YOUR) (OTC: YOURF) (FSE: HOB) (the “Company” or “YourWay“), a multi-state and consumer-centric House of Brands committed to redefining the way consumers and cannabis brands interact, today announced the Company’s common shares are trading on the OTCQB Venture Market (“OTCQB“) in the United States under the symbol, “YOURF”.
“Listing on the OTCQB is another milestone for YourWay as we continue to broaden awareness of the Company’s activities in the United States, including highlighting exciting growth opportunities for the Company,” said Jakob Ripshtein, Chairman, Board of Directors, YourWay. “By exposing YourWay to a larger market of investors, we look forward to expanding the Company’s shareholder base, and improving awareness, access and liquidity.”
YourWay’s common shares will continue to trade under the symbol “YOUR” on the Canadian Securities Exchange, and “HOB” on the Frankfurt Stock Exchange.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) (“OTC Markets Group“) operates the OTCQX® Best Market, the OTCQB® Venture Market and the Pink® Open Market for over 11,000 U.S. and global securities. Through its regulated OTC Link® Alternative Trading Systems, OTC Markets Group connects a diverse network of broker-dealers that provide liquidity and execution services. OTC Markets Group enables investors to easily trade through the broker of their choice and empowers companies to improve the quality of information available for their investors. To learn more about how OTC Markets Group creates better informed and more efficient markets, visit www.otcmarkets.com.
About YourWay Cannabis Brands
YourWay Cannabis Brands is a publicly traded multi-state operator with sales and operations in Arizona and California. Through building their own brands, partnering with others, and providing white-labelled product, they are dedicated to expanding their reach; remolding the cannabis industry and ultimately, redefining the way consumers and cannabis brands interact.
YourWay aims to connect with the cannabis consumer on a deeper level, utilizing decades of brand-building expertise and an integral understanding of the customer experience to create an intuitive suite of branded products that closely aligns with consumer need states. The YourWay portfolio is an all-encompassing house of brands designed to create a sense of belonging for every cannabis consumer regardless of their relationship with the plant. Please visit www.yourwaycannabis.com for the latest news and information about YourWay and its brands.
Website: www.yourwaycannabis.com
SOURCE YourWay Cannabis Brands
MIAMI, Jan. 31, 2022 (GLOBE NEWSWIRE) — Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, today issued a letter to shareholders from its Chief Executive Officer, Ben Kaplan.
Dear Fellow Shareholders,
Ehave is focused on progressing Psychedelics-to-Therapeutics by engineering novel compounds and new treatment protocols for treating brain health led by technology. We have built a network of like-minded scientists and mental health professionals combined with technology, who share our mission to create safe and effective therapeutics by leveraging clinical data to help us address mental health issues to achieve optimal patient outcomes.
Why Ehave is Important In The Psychedelic Ecosystem
Before I discuss the upward inflection points Ehave achieved in 2021, I would like to provide a reminder of the problem we are targeting and our mission to impact it. At its core, the problem is simple – In America, 21% of U.S. adults experienced mental illness in 2020 (52.9 million people), 5.6% of U.S. adults experienced serious mental illness in 2020 (14.2 million people), 16.5% of U.S. youth aged 6-17 experienced a mental health disorder in 2016, 6.7% of U.S. adults experienced a co-occurring substance use disorder and mental illness in 2020, and suicide is the 2nd leading cause of death among people aged 10-34. We are confident in our ability to deliver solutions because we have built a team that understands the challenges facing mental health.
Reflecting on 2021, I am very grateful for the accomplishments and progress we have made. As much of the heavy lifting has been completed, I am more positive than ever on both Ehave and the opportunities that lie ahead. Last year was a foundational year that set the stage for Ehave by developing breakthrough products and assembling a talented and expert team to execute our strategy for the future. As we move forward in 2022, we find ourselves strategically positioned with a strengthened balance sheet, a deep bench of experienced industry professionals, an exceptional portfolio of products and services, and an opportunity to provide an increased quality of mental health through data based psychedelic medicine. With a great deal of the development accomplished, we plan to engage with what I believe will be yet another transformative year for the company as we move towards monetizing Ehave’s investments by licensing our technology to other enterprises in an effort to advance research and commercialization of psychedelics.
Mycotopia Therapies
On December 28, 2020 Ehave sold 100% of its Mycotopia Therapies (OTC: TPIA) subsidiary to 20/20 Global Inc. for $350,000 and 75.77% of 20/20 Global’s outstanding shares in order to maximize Mycotopia Therapies value for our shareholders. The company was subsequently renamed Mycotopia Therapies and is traded on OTC Markets under the symbol TPIA. Less than a year later, Mycotopia Therapies announced it had signed an LOI to explore a merger with Ei.Ventures that will form PSLY.COM in a $360 million transaction that includes applying to list the new company’s shares on NASDAQ. Fulfilling our promise to maximize Mycotopia Therapies value for our shareholders, Ehave announced plans to spin out 30% of its PSLY.COM holdings to Ehave shareholders on a pro-rata basis. We anticipate this happening in the first half of 2022.
Ei.Ventures’ flagship botanical psilocybin-based formulation Psilly is a whole-plant botanical psilocybin-based formulation, which is currently in the pre-clinical phase. The goal of the combined companies would be to complete pre-clinical and phase 1 trials and launch therapeutic Psilly into jurisdictions where psilocybin is legal. Ei.Ventures recently announced the acquisition of a 12×12 estate in The Sandbox, a virtual world where players can build, own, and monetize their gaming experiences on the Ethereum blockchain, which represents the third-largest land sale in the Metaverse valued at $2.22M. The land will be called PSLY.COM, the name of the soon-to-be merged company of Ei.Ventures with Mycotopia Therapies.
KetaDASH Home Delivery Service
Early in 2021, Ehave announced plans for KetaDASH, a platform for medical practitioners to administer ketamine intravenously to patients at home. KetaDASH has evolved into a managed service organization focused on the psychedelic sector, with the ability to help doctors increase both patients and the revenue, as well as expand and manage their practice. Widely used for pain after certain medical procedures, Ketamine is now being studied as a treatment for major depression, though it has not yet been approved by the FDA to treat depression. We believe Ketamine has rapid antidepressant properties in unipolar and bipolar depression. An antidepressant effect has been reported as soon as 40 minutes after ketamine infusions, which is why we are rolling out our ketamine home delivery platform. The backbone for KetaDASH will be Ehave’s expertise in the area of digital therapeutics, which has been developed through years of testing in the area of mental healthcare. Ehave’s digital therapeutics insight will empower patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools.
After years of continued work to develop its proprietary digital therapeutics technology, Ehave is ahead of other psychedelic companies that are in the process of building integrated technical platforms and comprehensive toolsets to deliver psychedelic inspired medicines and experiential therapies combined with digital therapeutics. Ehave also plans to launch brain mapping ketamine clinical trials using Brain Scientific technology in Miami with Tristar Wellness. The clinical trial, originally planned for year-end 2021, but delayed by Covid, will establish the statistical correlation between the ketamine treatment and patient improvement from the disorders. We plan to utilize an Institutional Review Board, which will review all research involving human subjects and implement policies and procedures regarding such research.
KetaDASH offers Ehave shareholders our fastest path to becoming a revenue generating company. KetaDASH offers ketamine for treatment resistant depression, anxiety, PTSD, and other conditions. After a short telemedicine visit, an experienced nurse will arrive at your location of choice to administer the sublingual treatment. Ehave plans to start its KetaDASH service this month in the San Francisco and Sacramento California area. Through our agreement with the telemedicine platform getheally.com, KetaDASH will have access to doctors in all 48 continental states. This will allow us to scale KetaDASH and expand it quickly. It is important to note Ehave and KetaDASH comply with all federal regulations. In an effort to continue to be compliant, our business plan calls for pairing each patient with a nurse to administer the treatment. I would like to invite you to learn more about the products and services offered by KetaDASH at www.ketadash.com.
MegaTeam
Ehave’s MegaTeam assessment and rehabilitation products are built on established methodologies for the measurement of cognitive abilities in populations with attention deficit hyperactivity disorder (“ADHD”). The MegaTeam products embed cognitive assessment and rehabilitation tasks within an engaging video game environment. iOS/Android Versions are currently being added to play stores. Ehave’s Ninja Reflex is a video game intervention for kids with neurodevelopmental disorders.
Ehave has conducted two Clinical Trials at the Hospital for Sick Children in Toronto for its MegaTeam-videogame as an intervention/treatment for ADHD. One has been closed and the second is ongoing.
Our initial trial started in September, 2016 and ended in April, 2017 with a pilot study of 35 participants. The trial showed the longer you practice on the game, the better your ability to stop a speeded motor response is, and the better you get at manipulating information in short-term working memory. https://clinicaltrials.gov/ct2/show/NCT02827188.
Our second trial started April, 2018 and is ongoing under supervision of Dr. Jennifer Crosbie with over 100 patients recruited to date. The Clinical Trial was sponsored by The Hospital for Sick Children in Ontario, Canada and was titled Cognitive Restructuring in ADHD: Functional Training (CRAFT) study. The objective of the study was to develop a non-pharmacological intervention program for children with ADHD. The Canadian government invested over $1,000,000.00 in grants in this closed study. Investors can find more information on our Clinical Trial on the U.S. National Library of Medicine’s Clinical Trials website at https://clinicaltrials.gov/ct2/show/NCT03502239.
HPPD Study with University of Melbourne
In 2021 our research took us to the other side of the world as we announced a partnership with the University of Melbourne to gather data and bio-markers to target Hallucinogen Persisting Perception Disorder (“HPPD”). We look forward to continuing this partnership into 2022 and will look to create bio lines and a testing revenue model as well as screening products capable of indicating HPPD. Hallucinogen-persisting perception disorder, or HPPD, can cause a person to keep reliving the visual element of an experience caused by hallucinogenic drugs. Ehave believes the key to widespread acceptance for psychedelics is a focus on the good as well as the bad, which is why we are investing in this series of studies on HPPD.
Currently, researchers at the University of Melbourne have completed the necessary documents required for university ethics approval for online study of HPPD, and are updating the ethics documents for re-submission before the pilot can take place This includes recruitment, plain language statement, consent form, and debriefing. The researchers have also submitted a full ethics application, and are awaiting a decision on minimal risk accreditation. They have received preliminary approval for the pilot project to be considered “low or negligible risk,” and received ethics board review feedback on the submission seeking clarification on the role of funders regarding data, as well as minor clarifications on surveys/tasks being used.
MetaHealthU
With the growing popularity of the Metaverse, we believe 2022 will be a great year for our MetaHealthU, a mobile application platform that empowers individuals to take complete control of their health and their healthcare data. With Meta HealthU, users can securely track all their health data from wearables, Electronic Health Records Systems (EHRs), Doctors and Medical Labs. The app is available for iOS 11.0 or later, Android, and includes a “digital file cabinet” for medical records. Features include easy to use navigation and search capabilities for users to collect, file and tag their medical records on their mobile device. Users can log into their patient portals on various healthcare systems and medical labs and download their medical records in the digital file cabinet.
The social connectivity aspects of this version of the app usher in a new era of digital health where users create and become part of their ‘social health network’. Meta HealthU users can create their own health-oriented Campaigns and Challenges and invite their friends, family and colleagues to participate in these Campaigns and Challenges. Combining the social aspects of health with the ability for users to create their own health-related challenges and campaigns provides powerful incentives to be and to stay healthy. For example, users can chip in a participation fee in the form of OmPoints to a “Challenge Purse” and compete to win OmPoints from the purse. The digital wallet connectivity with the blockchain enables users to bundle and share their health records in a secure and seamless way while earning OmPoints. The digital wallet stores reward points users can accumulate by participating in health-related Campaigns and Challenges. Institutions, such as Hospitals and Pharmaceutical companies, can fund health-related campaigns or research, create cohorts and invite them to participate. Using the Campaign Wizz Bridge Application Dashboard, they can reward participants with OmPoints for taking part in clinical trials or for adopting a healthy lifestyle. Users will be able to redeem OmPoints they have accumulated over time for Amazon Gift Cards or other gift cards which they can use for purchases.
Our health wallet is based on MyEtherWallet which will in the future allow users to mint their health records as an NFT. The function of having an immutable record of ownership or agreement minted onto a blockchain has such rich potential to impact so many industries. The most exciting use cases beyond the current iteration of NFTs include medical records, clinical trial results, and retreat results.
Ehave Dashboard Is Now Part Of MetaHealthU
The Ehave Dashboard is our flagship product. Over the years it has evolved into a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insight using Blockchain technology. Through our technology we offer Offline Encrypted Digital Records Empowering Healthcare providers and patients and it’s a powerful machine learning and artificial intelligence platform using artificial intelligence to extract deep insights from audio, video and text to improve research with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools.
Ehave has developed a medical record exchange plugin that will allow patients to own their own healthcare records and work more closely with medical professionals and psychedelic researchers to target conditions that are poorly addressed by the healthcare system today, such as chronic diseases, treatment-resistant depression, and neurological disorders. Plans for 2022 include monetizing this asset. Ehave also formed a partnership for our Dashboard with Health Wizz, a Digital Healthcare IT venture focused on FHIR interoperability and employee wellness, and BurstIQ, the leading provider of blockchain-based data solutions for the healthcare industry. Ehave will use BurstIQ’s privacy-protecting technology to link clinical trial data using its Dashboard and AI to health data from various sources, including wearables, lab reports, and doctor and hospital visits. Ehave allows us to provide our Dashboard users an opportunity to manage their personal medical records and retrieve them through a dedicated instance on the AWS (Amazon Web Services) platform.
Also in 2022, Ehave plans to monetize the AI technology it licensed from Vastmindz to expand the Ehave Dashboard and Ehave Medical App offerings. The AI technology will provide the Ehave Dashboard and Ehave Medical App with the ability to identify an individual’s physiological condition, such as Heart Rate, Heart Rate Variability (HRV), Respiration Rate, Oxygen Saturation Level, and other vital statistics. These changes in physiological condition will be identified by extracting information about changes in light absorption on an individual’s facial skin. No different than taking a selfie, the changes are captured within the RGB pixel values of camera frames and converted into various physiological vitals utilizing Vastmindz proprietary AI.
In Closing
Also in 2021, Ehave appointed Jeffrey D. Kamlet, MD, FASAM, DABAM to the position of Chief Medical Officer. Dr. Kamlet brings more than 30 years of Internal Medicine, Addiction Medicine and Pain Management experience to Ehave. He has also served as a Principal Investigator on over 20 major pharmaceutical clinical trials.
Moving forward we will continue to pursue a listing on a Canadian Stock Exchange and uplisting to the OTCQB Exchange, both of which were delayed in 2021 due to Covid. We will also continue to pursue closing the acquisition of 100% of Moksha Digital Software Pvt. Ltd., a provider of medical imaging software and the creator of the FDA cleared CuriePACS and CurieRIS solutions.
Our diverse team is our strength. As a result, we actively promote diversity and inclusion in all our projects by ensuring minority, women-owned, and small business participation in our industry. In 2021, we announced our firm commitment to sustainability and corporate responsibility, and we believe non-financial factors, such as environmental, social, and governance are a major part of identifying material risks and growth opportunities.
We look forward to sharing our accomplishments in the coming year as we strive to create value for our customers, shareholders, and employees – and we thank all our stakeholders for their support of our mission.
Sincerely,
Ben Kaplan
Chief Executive Officer
About Ehave, Inc.
Ehave, Inc. is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, psychedelics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes meeting privacy and HIPAA & GDPR Compliant. Our main product is the Ehave Dashboard which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insight using Blockchain technology. The Ehave dashboard offers Offline Encrypted Digital Records Empowering Healthcare providers and patients and it’s a powerful machine learning and artificial intelligence platform using artificial intelligence to extract deep insights from audio, video and text to improve research with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools.
Forward-Looking Statement Disclaimer
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.
For Investor Relations, please contact:
David Kugelman
(866) 692-6847
(404) 281-8556 Mobile and WhatsApp
Skype: kugsusa
ir@ehave.com
Vancouver, B.C. – January 21, 2022: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (“Better Plant” or the “Company”), a wellness company that develops and sells plant-based products, is pleased to announce it has streamlined operations and plans to reduce expenses by discontinuing the brand Urban Juve and discontinuing the Jusu Bar juice business. Better Plant plans to focus its resources in the near term on the Jusu Wellness line of products. It also plans to look at potential acquisitions and other opportunities to build value for shareholders.
Urban Juve Provisions Inc. a wholly owned subsidiary of Better Plant, which has been selling the Urban Juve ayurvedic inspired line of 11 skincare products and two hand sanitizer products, will take all of its product offline, and the brand Urban Juve will be discontinued. Urban Juve formulas and other intellectual property will be transferred to Jusu Wellness Inc., another wholly owned subsidiary of Better Plant. Jusu Wellness currently makes and sells over 40 plant-based products, including cleaning products, skin care products and body products.
With the assets from Urban Juve, Jusu Wellness will have an expanded catalog of formulas and may be able to take advantage of some of Urban Juve’s key account and retailer relationships to grow its business. This past quarter Jusu Wellness added five new retailers including Yes Wellness, The Found House, Echo Wofford, Old Joy Gift Boxes and Fido’s World.
Jusu Bars is winding down it’s juice operations. Operations of Jusu Bar at Cadboro Bay in Victoria, British Columbia will cease in February 2022. Juice manufacturing of new products has ceased, and the online ordering platform will stop selling Jusu juices in January 2022.
Both Urban Juve and Jusu Bars have been money losing businesses and so it’s expected that discontinuing them will improve Better Plant’s financial position by reducing future losses, although there will be a reduction in revenues and some assets may be impaired.
Perry Chua has resigned as Chief Creative Officer, effective January 14, 2022, but will continue to work with Better Plant as a consultant. Better Plant continues to act as an incubator for new businesses by providing branding, marketing, and accounting services to emerging companies. In his role as consultant, Mr. Chua will continue to oversee Better Plant’s creative team in the provision of these services.
About Better Plant Sciences Inc.:
Better Plant has a catalog of hundreds of product formulas and develops, commercializes, markets, and sells over 50 products through the brands Jusu Wellness and NeonMind. Jusu Wellness products are sold direct to consumer goods through Jusu’s online eCommerce platform as well as through a network of online and brick-and-mortar retail stores. Better Plant has a talented team with expertise in digital design, branding, eCommerce, and digital marketing and offers marketing, branding, financial, and other services to companies with emerging businesses.
For more information on Jusu Wellness, visit getjusu.com or follow Jusu Wellness on Instagram or Facebook.
For more information on Better Plant, visit betterplantsciences.com or follow on Instagram, Twitter or LinkedIn.
Penny White, President & CEO
1-833-515-2677
Investor Relations:
Alexandra Dumanski
invest@betterplantsciences.com
1-833-515-2677
Sales Inquiries:
Amber Allen, Head of Sales
604-808-8118
The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen. Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets. Better Plant cautions readers not to place undue reliance on forward-looking statements provided by Better Plant, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better Plant expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has filed a combined Clinical Trials of Investigational Medicinal Products and Ethics Approval application, with the United Kingdom Medicines and Healthcare Products Regulatory Agency (“UK MHRA”). This was accomplished via the combined review service, which provides for a single application route for its planned Phase 1 clinical human study of AP-188 (“N,N-dimethyltryptamine” or “DMT”). DMT is a known psychedelic compound that is part of the tryptamine family.
The Company announced on November 19, 2021, that it had received positive feedback at a scientific advice meeting from the UK MHRA for its planned Phase 1 DMT Stroke study.
The primary focus of the Phase 1 DMT study is to investigate prolonged intravenous infusion of DMT, for durations which have never been clinically studied. The resulting data generated will help the Company to plan both its Phase 2 acute stroke and rehabilitation studies more effectively.
“We look forward to getting our DMT clinical stroke program started with our Phase 1 study at Hammersmith Medicines Research in the UK,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. “This study will provide important information on dosage and duration of our new DMT IV formula to help us better plan for our Phase 2 study where we plan to test the drug with both acute and recovering stroke patients.”
Phase 1 DMT Stroke Study Summary
The purpose of the study is to identify the safety, tolerability, and pharmacokinetics of DMT when administered as an intravenous bolus followed by prolonged infusion. The first part of the study will use a single-escalating dose design aimed at identifying the maximum sub-psychedelic dose, while the second part will test the effects of repeated administrations of this dose. There will be up to 96 healthy volunteers enrolled across the two parts of the study which will include both psychedelic experienced and psychedelic naïve patients.
About DMT
N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug producing effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin. DMT occurs naturally in many plant species and animals including humans and has been used in religious ceremonies as a traditional spiritual medicine by indigenous people in the Amazonian basin. DMT can also be synthesised in a laboratory.
Algernon has filed provisional patents for new forms of DMT, in addition to formulation, dosage and method of use claims for ischemic stroke. The Company has also filed claims for combination therapy of DMT and stroke rehabilitation including Constraint Induced Movement Therapy.
About Algernon Pharmaceuticals Inc.
Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
Calgary, AB – TheNewswire – January 10, 2022 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”) announces that Rami Batal has been replaced as Chief Executive Officer (“CEO”) of the Company and its subsidiaries. For the present time, the Company has appointed Nick Karos as CEO, effective immediately. Mr. Karos had recently been appointed as a Capital Markets consultant to the Company.
“We are grateful for Rami’s leadership and many contributions,” said Chief Ian Campbell, Chair of the UI Board of Directors. “We wish Rami all the best.”
Mr. Karos is based in Los Angeles, USA, and is a seasoned financier. His career includes senior roles with US investment banks, including serving at Piper Jaffray as head of Nasdaq Trading and Agency Services, and most recently as CEO of Private Trading Group, which has provided business development and capital raising services for several successful start-up ventures.
Mr. Karos said “I’m very excited to work with the talented partners at UI to move towards our goal of conducting clinical trials with Health Canada. Universal Ibogaine’s goal is to transform the addiction treatment model using ibogaine as the cornerstone of our new addiction treatment protocol. Addiction is a disease that affects society like none other, and we believe our ground-breaking protocol will give patients and families a better path towards long-term recovery.”
The Board of Directors will immediately begin an executive search process for selecting a new CEO. Mr. Karos remains a short list candidate for the long term position.
UI is a life sciences company, with a goal to develop a platform of addiction treatment clinics, which may eventually use ibogaine as a primary modality for the interruption and ideally cessation of addictions to primarily opioids such as oxycodone, heroin, fentanyl, as well as alcohol, cocaine, and other stimulants.
UI separately plans to clinically develop ibogaine, a natural plant substance, as an authorized addiction interruption medicine for the treatment of Opioid Use Disorder. A Clinical Trial Application to Health Canada is being developed to undertake clinical trials in Canada, aimed at proving the safety and efficacy of the use of ibogaine for this purpose. In the longer term, UI plans to introduce ibogaine into the addiction treatment protocols to be used in its’ future facilities.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such as “plans”, “expect”, “project”, “intend”, “will”, “believe”, “anticipate”, “estimate”, “scheduled”, ”potential”, or other similar words, or statements that certain events or conditions “may”, “should” or ”could” occur. The forward-looking statements and information are based on certain key expectations and assumptions made by UI. Although UI believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because UI can give no assurance that they will prove to be correct.
Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks, which include, but are not limited to, risks that required regulatory approvals are not obtained. The reader is cautioned that assumptions used in the preparation of such information, although considered reasonable by UI at the time of preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on forward-looking information, which speaks only to conditions as of the date hereof. UI does not undertake any obligation to release publicly any revisions to forward-looking information contained herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.
For further information:
Investor Relations: Dugan Selkirk – IR Manager
dugan.selkirk@universalibogaine.com
Media Contact: Cathy Fernandes – VP, Marketing & Communications cathy.fernandes@universalibogaine.com
